7-OH & Kratom Dependence Treatment in Wisconsin

No for ordinary consumer use. Wisconsin classifies 7-hydroxymitragynine as a Schedule I controlled substance and does not provide a permitted retail concentration threshold.

Under Wisconsin Statutes § 961.14, 7-hydroxymitragynine is specifically listed as Schedule I. The provision applies to materials, compounds, mixtures, or preparations containing any quantity of the listed substance.

Yes for ordinary consumer use. Wisconsin classifies mitragynine, the principal alkaloid in kratom, as a Schedule I controlled substance. Because ordinary kratom contains mitragynine, kratom products containing it fall under Wisconsin’s controlled-substance restrictions.

There is no lawful general consumer purchasing age and no Kratom Consumer Protection Act framework. Wisconsin regulates kratom through its Uniform Controlled Substances Act rather than through age or concentration limits.

Wisconsin already lists both mitragynine and 7-hydroxymitragynine as Schedule I controlled substances under Wisconsin Statutes § 961.14. There is no permitted numerical 7-OH retail threshold.

Separately, the DEA’s July 2026 federal Notice of Intent proposes temporary federal Schedule I treatment for 7-OH only above specified thresholds. Wisconsin is already more restrictive because state law directly lists 7-OH and mitragynine without an equivalent consumer concentration threshold.

Consider speaking with a medical provider before your supply ends, especially if you use 7-OH every day or experience withdrawal symptoms between doses.

Tell the provider the exact product you use, the amount per dose, how frequently you take it and whether you use any other substances. Avoid automatically replacing 7-OH with another concentrated or unregulated product.

There is no universal over-the-counter replacement for 7-OH.

The appropriate treatment depends on whether you were using it for pain, energy, anxiety, opioid withdrawal, cravings or to prevent withdrawal from 7-OH itself. A medical provider can evaluate the underlying reason and recommend appropriate treatment options.

Possible symptoms include restlessness, sweating, chills, body aches, nausea, stomach discomfort, diarrhea, difficulty sleeping, anxiety, irritability, low mood and cravings.

Symptoms can vary depending on the product, concentration, dose, frequency of use, length of use and other substances being taken.

There is no single established timeline that applies to every patient.

The duration and severity of withdrawal may be influenced by how much you use, how often you take it, how long you have used it, the concentration of the product, your health history and whether other substances are involved.

A provider can offer more individualized guidance after completing an evaluation.

Some people may be able to receive outpatient or telehealth support, while others require in-person detoxification or a higher level of care.

The safest setting depends on your level of dependence, withdrawal history, medical conditions, mental-health symptoms, use of other substances and available support at home.

Do not attempt to manage severe withdrawal or serious medical symptoms without professional help.

Eligible patients located in Wisconsin may receive a confidential online medical evaluation from DevotedDOc when an appropriately licensed provider is available.

The provider will determine whether telehealth care is appropriate or whether you need in-person treatment or a higher level of support.

A licensed provider may consider buprenorphine/naloxone in selected cases involving opioid-like dependence or opioid use disorder.

Suboxone is not automatically appropriate for everyone using 7-OH. A medical evaluation is required, and receiving an appointment does not guarantee that a particular medication will be prescribed.

Not everyone requires residential rehabilitation.

Depending on your symptoms and treatment needs, care may be provided through telehealth, outpatient medical treatment, counseling, intensive outpatient treatment, medically supervised detoxification or residential care.

A clinical evaluation helps determine the safest and most appropriate level of support.

7-hydroxymitragynine — abbreviated 7-OH, 7OH or 7-HMG — is one of several alkaloids that occur naturally in the kratom plant, Mitragyna speciosa, though only in small amounts in raw kratom leaf.

7-OH is not the same as kratom itself. Kratom refers to the whole botanical material, which contains many alkaloids beyond 7-OH. Commercial 7-OH tablets, gummies, shots and similar products may contain added, isolated or enhanced concentrations that are substantially different from traditional kratom leaf.

Regular use may lead to tolerance and physical dependence. A person who has become dependent may experience withdrawal symptoms, cravings or difficulty reducing use.

Needing more of the product to achieve the same effect or taking it mainly to avoid feeling sick may be signs that medical support is needed. FDA has documented cases of substance-use disorder, tolerance, cravings and withdrawal associated with kratom products.

These are synthetically derived compounds related to 7-hydroxymitragynine. Wisconsin already lists both mitragynine and 7-hydroxymitragynine as Schedule I controlled substances. The DEA has also issued notices of intent to place these related substances in Schedule I under federal law. Federal status may have changed since this page’s legal review date.

DevotedDOc provides private medical care through secure telehealth appointments.

Patient information is handled according to applicable privacy requirements and DevotedDOc’s published privacy practices.